Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effect of the chronic treatment of type 2
diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin
signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a
potent, highly specific inhibitor of renal glucose transport [SGLT2].
Phase:
N/A
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)